ALK Alternative Transcript (ATI)

CI-VAR-00000195Explore in graph →CIViC 839

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Cutaneous Melanoma1
ALK Alternative Transcript (ATI)	Crizotinib	Predictive	C	Supports Sensitivity Response	4	accepted	EID1936 Expression of an alternative ALK transcript (ATI), encompassing exons 20–29 preceded by ~400 base pairs (bp) of intron 19, but not exons 1–19 was identified in three samples of thyroid cancer and mela… (full text at CIViC) PMID 26444240 · Wiesner et al., 2015 · Open in CIViC	civic
Malignant Neoplasm1
ALK Alternative Transcript (ATI)	Crizotinib	Predictive	D	Supports Sensitivity Response	4	submitted	EID7646 Expression of the ALK alternative transcript isoform (ATI) in Ba/F3 cells resulted in phosphorylation of ALK and IL3-independent growth in vitro, while ALK ATI expressing NIH-3T3 cells induced tumorig… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Melanoma1
ALK Alternative Transcript (ATI)	Alectinib + ALK Inhibitor ASP3026 + Ceritinib + Crizotinib + EntrectinibSubstitutes	Predictive	D	Does Not Support Sensitivity Response	3	submitted	EID7484 Melanoma cell lines and xenografts expressing the ALK ATI variant did not respond to treatment with ALK inhibitors, while fusion ALK expressing cell lines and xenografts were sensitive. PMID 29054983 · Couts et al., 2018 · Open in CIViC	civic

Mucosal Melanoma1
ALK Alternative Transcript (ATI)	Entrectinib	Predictive	C	Does Not Support Sensitivity Response	4	accepted	EID7421 ALK expression was analyzed in 45 melanoma patient-derived xenografts (PDXs), with 11/45 showing ALK expression. Four PDX tumours had only wild-type ALK expression, four had only ALK alternative trans… (full text at CIViC) PMID 29054983 · Couts et al., 2018 · Open in CIViC	civic